(EMAILWIRE.COM, October 27, 2018 )
The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period.



According to the new market research report "Pulmonary Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities.

Don’t miss out on business opportunities in Pulmonary/ Respiratory Drug Delivery Market.
Speak to our analyst and gain crucial industry insights that will help your business grow: https://www.marketsandmarkets.com/speaktoanalyst.asp?id=179682410

The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route of drug delivery, increasing technological developments in the form of smart/digital inhalers and rising incidences of respiratory diseases such as COPD, asthma, and cystic fibrosis.
The respiratory drug delivery market by formulation segment is further divided into device type and formulation type. The market, by device type, is categorized into metered dose inhalers, dry powder inhalers, and nebulizers. The dry powder inhalers segment is expected to witness the highest growth during the forecast period due to the advantages associated with the use of these inhalers, such as short administration & preparation time, ease of use, and fewer irritant effects.
The pulmonary drug delivery market, based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles.

Browse and in-depth TOC on "Pulmonary/ Respiratory Drug Delivery Market"
104 – Tables
33 - Figures
150 - Pages
View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/pulmonary-respiratory-drug-delivery-market-179682410.html

The pulmonary drug delivery market, based on formulation type, is segmented into suspension aerosol, solution aerosol, and dry powder formulation. The dry powder formulation segment is expected to witness the highest growth during the forecast period due to improved dosage accuracy, minimized dosage variability, and improved flow of drug particles.
Based on applications, the market is segmented into asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other applications (cardiovascular disease, diabetes, respiratory therapy, and treatment of patients on ventilators). The asthma segment accounts for the major share in the market during the forecast period due to increasing prevalence of asthma across the globe.

Request for Free Sample Report @
https://www.marketsandmarkets.com/requestsample.asp?id=179682410

Currently, North America dominates the pulmonary drug delivery devices market, and Asia represents the second-largest regional market. Moreover, the Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing geriatric population, growing adoption of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region.
Prominent players in the pulmonary drug delivery market include GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).

Browse Adjacent Markets @ Medical Devices Market Research Reports & Consulting

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact Us:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/pulmonary-respiratory-drug-delivery-market.asp
Visit Our Website: https://www.marketsandmarkets.com